David S. Pires, Monica Ammon Fernandez, Adriana S. A. Pereira, Marcelo Rosado Fantappié, Dante Rotili, A. Ganesan, Eduardo José Lopes Torres, Raymond J. Pierce, Sergio Verjovski-Almeida, Frank J. Dekker, M. Teresa Borrello, Marina de Moraes Mourão, Dina Robaa, Murilo S. Amaral, Isabel Caetano de Abreu da Silva, Amanda Roberta Revoredo Vicentino, Gilbert de Oliveira Silveira, Julien Lancelot, Silvana C. Thiengo, Fernanda Sales Coelho, Antonello Mai, Wolfgang Sippl, Vitor Coutinho Carneiro, Universidade Federal do Rio de Janeiro (UFRJ), Instituto Butantan [São Paulo], Universidade de São Paulo (USP), University of Groningen [Groningen], Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Universidade do Estado do Rio de Janeiro [Rio de Janeiro] (UERJ), Martin-Luther-Universität Halle Wittenberg (MLU), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), University of East Anglia [Norwich] (UEA), Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP), This work was supported in part by a grant from the European Union’s Seventh Framework Programme under agreement no. 602080. MRF, was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nıvel Superior (CAPES) and Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Brazil. MRF, MMM, SVA are recipient of established investigator fellowship award from CNPq. Fellowships from FAPESP has supported GOS (2018/24015-0). RP received institutional support from Inserm, CNRS, Pasteur Institute of Lille and Lille University. AM was supported by PRIN 2016 (prot. 20152TE5PK) and AIRC 2016 (n. 19162) funds. W.S. and D.R. were supported by the European Regional Development Fund of the European Commission. EJLT was supported by FAPERJ JCNE (Productive Fellowship Program, grant 202.660/2018). FD was supported by the Netherlands Organization for Scientific Research (NWO), VIDI grant (723.012.005)., Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Medicinal Chemistry and Bioanalysis (MCB), Chemical and Pharmaceutical Biology, Bodescot, Myriam, Universidade de São Paulo = University of São Paulo (USP), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ)
Treatment and control of schistosomiasis still rely on only one effective drug, praziquantel (PZQ) and, due to mass treatment, the increasing risk of selecting for schistosome strains that are resistant to PZQ has alerted investigators to the urgent need to develop novel therapeutic strategies. The histone-modifying enzymes (HMEs) represent promising targets for the development of epigenetic drugs against Schistosoma mansoni. In the present study, we targeted the S. mansoni lysine-specific demethylase 1 (SmLSD1), a transcriptional corepressor, using a novel and selective synthetic inhibitor, MC3935, which was used to treat schistosomula and adult worms in vitro. By using cell viability assays and optical and electron microscopy, we showed that treatment with MC3935 affected parasite motility, egg-laying, tegument, and cellular organelle structures, culminating in the death of schistosomula and adult worms. In silico molecular modeling and docking analysis suggested that MC3935 binds to the catalytic pocket of SmLSD1. Western blot analysis revealed that MC3935 inhibited SmLSD1 demethylation activity of H3K4me1/2. Knockdown of SmLSD1 by RNAi recapitulated MC3935 phenotypes in adult worms. RNA-Seq analysis of MC3935-treated parasites revealed significant differences in gene expression related to critical biological processes. Collectively, our findings show that SmLSD1 is a promising drug target for the treatment of schistosomiasis and strongly support the further development and in vivo testing of selective schistosome LSD1 inhibitors., Author summary Schistosomiasis mansoni is a chronic and debilitating tropical disease caused by the helminth Schistosoma mansoni. The control and treatment of the disease rely almost exclusively on praziquantel (PZQ). Thus, there is an urgent need to search for promising protein targets to develop new drugs. Drugs that inhibit enzymes that modify the chromatin structure have been developed for a number of diseases. We and others have shown that S. mansoni epigenetic enzymes are also potential therapeutic targets. Here we evaluated the potential of the S. mansoni histone demethylase LSD1 (SmLSD1) as a drug target. We reported the synthesis of a novel and potent LSD1 inhibitor, MC3935, and show that it selectively inhibited the enzymatic activity of SmLSD1. Treatment of juvenile or adult worms with MC3935 caused severe damage to the tegument of the parasites and compromised egg production. Importantly, MC3935 proved to be highly toxic to S. mansoni, culminating in the death of juvenile or adult worms within 96 h. Transcriptomic analysis of MC3935-treated parasites revealed changes in the gene expression of hundreds of genes involved in key biological processes. Importantly, SmLSD1 contains unique sequences within its polypeptide chain that could be explored to develop a S. mansoni selective drug.